Cytosorbents Corp
NASDAQ:CTSO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.6215
1.31
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Cytosorbents Corp
NASDAQ:CTSO
|
42.5m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
188.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
188.5B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
137.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
135.3B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
129.9B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
49.3B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
55.3B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
49B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.3B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Cytosorbents Corp
Glance View
CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Monmouth Junction, New Jersey and currently employs 221 full-time employees. The company went IPO on 2005-06-17. The firm is engaged in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via its polymer adsorption technology. The firm's lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy and pancreatitis. Its other products include animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. The firm's product candidates under development includes CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent and porous polymer beads.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Cytosorbents Corp is -30.8%, which is above its 3-year median of -64.2%.
Over the last 3 years, Cytosorbents Corp’s Net Margin has increased from -114.6% to -30.8%. During this period, it reached a low of -114.6% on Sep 30, 2022 and a high of -28.4% on Jun 30, 2025.